Connor, Clark & Lunn Investment Management (CC&L)
GNCA

Connor, Clark & Lunn Investment Management (CC&L)’s Genocea Biosciences, Inc. GNCA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,214
Closed -$91K – 1042
2016
Q3 		$91K Sell
2,214
-1,526
-41% -$59.9K ﹤0.01% 781
2016
Q2 		$123K Sell
3,740
-3,351
-47% -$123K ﹤0.01% 784
2016
Q1 		$439K Sell
7,091
-747
-10% -$23.7K ﹤0.01% 595
2015
Q4 		$330K Buy
7,838
+4,300
+122% +$205K ﹤0.01% 611
2015
Q3 		$194K Buy
+3,538
New +$351K ﹤0.01% 645

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GNCA Position: Q4 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2016, closing a stake of 2,214 shares — an estimated $91K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GNCA in Q3 2015 and held it in 5 quarters. The position peaked at $439K in Q1 2016. 47 funds tracked by Wall St. Rank hold GNCA as of Q4 2016.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Genocea Biosciences, Inc. position as of Q4 2016 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 2,214 Genocea Biosciences, Inc. shares in Q4 2016, an estimated $91K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Genocea Biosciences, Inc. in Q3 2015 and held it in 5 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Genocea Biosciences, Inc. position peaked at $439K in Q1 2016.
  • 47 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2016, filed 13 Feb 2017.